{"title":"T9","authors":"O. Shatova, D. Kaplun, I. Zinkovych","doi":"10.1016/j.ejcsup.2015.08.090","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Metformin is a antidiabetic drug with anticancer properties. However, the mechanism action by which metformin affects various cancer cells still unknown. It is known that tumor growth is accompanied by changes in the metabolic cascade that includes overproduction of lactate and adenosine. The adenosine is released into the extracellular environment and regulates differentiation, proliferation, and angiogenesis of tumor mass. We found that lactate is activator of key enzyme of adenosine metabolism – adenosine deaminase (ADA).</p></div><div><h3>Aim</h3><p>The aim of our study was to investigate the catabolism of adenosine in the tumor while taking metformin.</p></div><div><h3>Materials and methods</h3><p>In this study we investigated the level of adenosine, inosine, hypoxanthine and ADA activity in 15 women aged 46–76<!--> <!-->years, with breast cancer (BC) T2-4N1M0 (cancer tissues) during treatment with metformin, 1000<!--> <!-->mg per day for 3 months. Control group – 15 women aged 46–76<!--> <!-->years, with stage T2-4N1M0 breast cancer (cancer tissues) without metformin therapy.</p><p>Statistical analysis was performed using the license package StatSoft. Statistica 12.0.</p></div><div><h3>Results</h3><p>ADA activity during treatment with metformin was 2-fold increased: 12.1<!--> <!-->±<!--> <!-->2.49<!--> <!-->nmol/min*mg in comparison with 4.77<!--> <!-->±<!--> <!-->0.943<!--> <!-->nmol/min*mg. Concentration of catabolic products of adenosine degradation was increased before metformin therapy. Inosine level was 0.121<!--> <!-->±<!--> <!-->0.041<!--> <!-->micro<!--> <!-->mol/g tissue (BC tissues from women without metformin 0.042<!--> <!-->±<!--> <!-->0.015<!--> <!-->micro<!--> <!-->mol/g tissue). Hypoxanthine 2.45<!--> <!-->±<!--> <!-->0.428<!--> <!-->micro<!--> <!-->mol/g tissue (in comparison with 0.711<!--> <!-->±<!--> <!-->0.269<!--> <!-->micro<!--> <!-->mol/g tissue). Whereas, adenosine level in BC after metformin therapy was 0.226<!--> <!-->±<!--> <!-->0.148<!--> <!-->micro<!--> <!-->mol/g tissue (in comparison with 0.186<!--> <!-->±<!--> <!-->0.056<!--> <!-->micro<!--> <!-->mol/g tissue), that were not significantly different.</p></div><div><h3>Conclusion</h3><p>Thus, we have found that metformin significantly increases the rate of catabolism of adenosine, and this in turn reduces the inhibitory effect on the tumor microenvironment cytotoxic cells. Therefore, our data for the first time provide novel evidence for a mechanism that the anticancer activities of metformin are due to adenosine metabolism regulation.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"13 1","pages":"Pages 50-51"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.090","citationCount":"0","resultStr":"{\"title\":\"T9\",\"authors\":\"O. Shatova, D. Kaplun, I. Zinkovych\",\"doi\":\"10.1016/j.ejcsup.2015.08.090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Metformin is a antidiabetic drug with anticancer properties. However, the mechanism action by which metformin affects various cancer cells still unknown. It is known that tumor growth is accompanied by changes in the metabolic cascade that includes overproduction of lactate and adenosine. The adenosine is released into the extracellular environment and regulates differentiation, proliferation, and angiogenesis of tumor mass. We found that lactate is activator of key enzyme of adenosine metabolism – adenosine deaminase (ADA).</p></div><div><h3>Aim</h3><p>The aim of our study was to investigate the catabolism of adenosine in the tumor while taking metformin.</p></div><div><h3>Materials and methods</h3><p>In this study we investigated the level of adenosine, inosine, hypoxanthine and ADA activity in 15 women aged 46–76<!--> <!-->years, with breast cancer (BC) T2-4N1M0 (cancer tissues) during treatment with metformin, 1000<!--> <!-->mg per day for 3 months. Control group – 15 women aged 46–76<!--> <!-->years, with stage T2-4N1M0 breast cancer (cancer tissues) without metformin therapy.</p><p>Statistical analysis was performed using the license package StatSoft. Statistica 12.0.</p></div><div><h3>Results</h3><p>ADA activity during treatment with metformin was 2-fold increased: 12.1<!--> <!-->±<!--> <!-->2.49<!--> <!-->nmol/min*mg in comparison with 4.77<!--> <!-->±<!--> <!-->0.943<!--> <!-->nmol/min*mg. Concentration of catabolic products of adenosine degradation was increased before metformin therapy. Inosine level was 0.121<!--> <!-->±<!--> <!-->0.041<!--> <!-->micro<!--> <!-->mol/g tissue (BC tissues from women without metformin 0.042<!--> <!-->±<!--> <!-->0.015<!--> <!-->micro<!--> <!-->mol/g tissue). Hypoxanthine 2.45<!--> <!-->±<!--> <!-->0.428<!--> <!-->micro<!--> <!-->mol/g tissue (in comparison with 0.711<!--> <!-->±<!--> <!-->0.269<!--> <!-->micro<!--> <!-->mol/g tissue). Whereas, adenosine level in BC after metformin therapy was 0.226<!--> <!-->±<!--> <!-->0.148<!--> <!-->micro<!--> <!-->mol/g tissue (in comparison with 0.186<!--> <!-->±<!--> <!-->0.056<!--> <!-->micro<!--> <!-->mol/g tissue), that were not significantly different.</p></div><div><h3>Conclusion</h3><p>Thus, we have found that metformin significantly increases the rate of catabolism of adenosine, and this in turn reduces the inhibitory effect on the tumor microenvironment cytotoxic cells. Therefore, our data for the first time provide novel evidence for a mechanism that the anticancer activities of metformin are due to adenosine metabolism regulation.</p></div>\",\"PeriodicalId\":11675,\"journal\":{\"name\":\"Ejc Supplements\",\"volume\":\"13 1\",\"pages\":\"Pages 50-51\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.090\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ejc Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359634915000919\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634915000919","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Metformin is a antidiabetic drug with anticancer properties. However, the mechanism action by which metformin affects various cancer cells still unknown. It is known that tumor growth is accompanied by changes in the metabolic cascade that includes overproduction of lactate and adenosine. The adenosine is released into the extracellular environment and regulates differentiation, proliferation, and angiogenesis of tumor mass. We found that lactate is activator of key enzyme of adenosine metabolism – adenosine deaminase (ADA).
Aim
The aim of our study was to investigate the catabolism of adenosine in the tumor while taking metformin.
Materials and methods
In this study we investigated the level of adenosine, inosine, hypoxanthine and ADA activity in 15 women aged 46–76 years, with breast cancer (BC) T2-4N1M0 (cancer tissues) during treatment with metformin, 1000 mg per day for 3 months. Control group – 15 women aged 46–76 years, with stage T2-4N1M0 breast cancer (cancer tissues) without metformin therapy.
Statistical analysis was performed using the license package StatSoft. Statistica 12.0.
Results
ADA activity during treatment with metformin was 2-fold increased: 12.1 ± 2.49 nmol/min*mg in comparison with 4.77 ± 0.943 nmol/min*mg. Concentration of catabolic products of adenosine degradation was increased before metformin therapy. Inosine level was 0.121 ± 0.041 micro mol/g tissue (BC tissues from women without metformin 0.042 ± 0.015 micro mol/g tissue). Hypoxanthine 2.45 ± 0.428 micro mol/g tissue (in comparison with 0.711 ± 0.269 micro mol/g tissue). Whereas, adenosine level in BC after metformin therapy was 0.226 ± 0.148 micro mol/g tissue (in comparison with 0.186 ± 0.056 micro mol/g tissue), that were not significantly different.
Conclusion
Thus, we have found that metformin significantly increases the rate of catabolism of adenosine, and this in turn reduces the inhibitory effect on the tumor microenvironment cytotoxic cells. Therefore, our data for the first time provide novel evidence for a mechanism that the anticancer activities of metformin are due to adenosine metabolism regulation.
期刊介绍：
EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites.
EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.
Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.
EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
